Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Patients meeting criteria for the risk syndrome for psychosis have treatment needs including positive and negative symptoms and cognitive impairment. These features could potentially respond to NMDA glycine-site agonists. The present objective was to determine which symptoms or domains of cognition promise to show the greatest response to glycine in risk syndrome patients. We conducted two short-term pilot studies of glycine used without adjunctive antipsychotic medication. In the first trial, 10 risk syndrome subjects received open-label glycine at doses titrated to 0.8 g/kg/d for 8 weeks, followed by discontinuation and 16 weeks of evaluation for durability of effects. In the second, 8 subjects were randomized to double-blind glycine vs. placebo for 12 weeks, followed by open-label glycine for another 12 weeks. Patients were evaluated every 1–2 weeks with the Scale Of Psychosis-risk Symptoms (SOPS) and before and after treatment with a neurocognitive battery. Within-group and between-group effect sizes were calculated. Effect sizes were large for positive (open-label within-group 1.10, double-blind between-group –1.11) and total (–1.39 and –1.15) symptoms and medium-to-large (–0.74 and –0.79) for negative symptoms. Medium or large effect sizes were also observed for several neurocognitive measures in the open-label study, although data were sparse. No safety concerns were identified. We conclude that glycine was associated with reduced symptoms with promising effect sizes in two pilot studies and a possibility of improvement in cognitive function. Further studies of agents that facilitate NMDA receptor function in risk syndrome patients are supported by these preliminary findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationThe Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · cited 1×
“Evidence suggests NMDAR hypoactivity may connect to other prominent models of psychosis (Feinberg, 1982; Howes and Kapur, 2009; McGlashan and Hoffman, 2000) by contributing to the development of dopamine hyperactivity in striatum (Carlsson et al., 1999; Laruelle et al., 2003) and cortical synaptic…”
BackgroundDesign and analysis of pilot studies: recommendations for good practice
Lancaster, G. A., Dodd, S., & Williamson, P. R. (2004) · Journal of Evaluation in Clinical Practice · doi:10.1111/j..2002.384.doc.x · Cited by 2,572
Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
Feinberg, I. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90038-3 · Cited by 1,395
Rapid Spine Delivery and Redistribution of AMPA Receptors After Synaptic NMDA Receptor Activation
Shi, S.-H., Hayashi, Y., Petralia, R. S., Zaman, S. H., Wenthold, R. J., Svoboda, K., & Malinow, R. (1999) · Science · doi:10.1126/science.284.5421.1811 · Cited by 1,276 · cited 1×
“…2009; McGlashan and Hoffman, 2000) by contributing to the development of dopamine hyperactivity in striatum (Carlsson et al., 1999; Laruelle et al., 2003) and cortical synaptic plasticity deficits (Collingridge and Singer, 1990; Newcomer and Krystal, 2001; Olney et al., 1999; Shi et al., 1999).”
BackgroundMcGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056 · cited 2×
“Intervention studies have begun to address these patients’ prevention needs (Amminger et al., 2010; McGlashan et al., 2006; McGorry et al., 2002; Morrison et al., 2004; Yung et al., 2011), and some have started to investigate current clinical state as a treatment target (Amminger et al., 2010;…”
BackgroundNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Morrison, A. P., French, P., Walford, L., Lewis, S. W., Kilcommons, A., Green, J., Parker, S., & Bentall, R. P. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.4.291 · Cited by 740
. Caution regarding the use of pilot studies to guide power calculations for study proposals.
Kraemer, H. C., Mintz, J., Noda, A., Tinklenberg, J., & Yesavage, J. A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.484 · Cited by 702 · cited 1×
“The first pilot study assessed whether the size of any beneficial effect of glycine in this population promises to be clinically meaningful (Kraemer et al., 2006) and what might best be identified as the principal therapeutic target in future studies.”
Background
Cited by
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00098-x · Cited by 148
Self-citationMei, C., van der Gaag, M., Nelson, B., Smit, F., Yuen, H. P., Berger, M., Krcmar, M., French, P., Amminger, G. P., Bechdolf, A., et al. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102005 · Cited by 143
Metadata
- Authors
- Woods, S. W., Walsh, B. C., Hawkins, K. A., Miller, T. J., Saksa, J. R., D'Souza, D. C., Pearlson, G. D., Javitt, D. C., McGlashan, T. H., & Krystal, J. H.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 23
- Issue
- 8
- Pages
- 931-940
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2032515910
- Cited by
- 60
- References
- 17
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. https://app.cochat.ai/papers/10.1016/j.euroneuro.2012.09.008
- The paper
- Woods, S. W., Walsh, B. C., Hawkins, K. A., Miller, T. J., Saksa, J. R., D'Souza, D. C., Pearlson, G. D., Javitt, D. C., McGlashan, T. H., & Krystal, J. H. (2013). Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2012.09.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.